previously unmet clinical conditions and offer a potential solution to the social and economic burden associated with an aging population [1, 2] . Human mesenchymal stem/stromal cells (hMSCs) are a promising cell therapy candidate for the treatment of numerous clinical indications [3] , however, a transformation is required in the way we isolate, manufacture, characterise and deliver these therapies to ensure they are both efficacious and affordable [2, 4] . Manufacture of hMSCs requires in vitro expansion to increase the available number of cells to meet clinical demand, however progress is impeded by the lack of advanced methods for the isolation and expansion of cells that are scalable, amenable for automation and closed.
Many allogeneic processes still require manual intervention which has significant quality and cost implications [5] , and developing reproducible, consistent bioprocesses is still a major challenge. Even when a scale-out approach is to be employed (e.g. for autologous therapies), there is a significant practical challenge of manipulating, processing and segregating multiple production batches in an aseptic, closed manner. Such processes demand small units for manufacture in which line segregation is a priority in order to avoid product-patient mismatch and disease transmission. As such, there is an industrial trend toward automated systems as it is increasingly recognised that such systems facilitate consistent manufacture and will play a pivotal role in the translation of cell therapies by improving quality control, process economics, scalability, process capability and provide a platform for understanding process variation and optimisation [6] .
Through AUTOSTEM (European Commission Horizon 2020 funded research and innovation actions), academic and industrial groups from across the EU are working in collaboration to take a holistic approach to enable large-scale hMSC production, at clinical-grade quality, by implementing a robotic automated pipeline for cell isolation and culture [7] . AUTOSTEM builds on the ground-breaking work of the StemCellFactory project [8] distribution. There is a need to improve and standardise isolation procedures and to this end, we will be using newly developed antibody selection methods developed by members of the consortium that target the vast majority of CFU-f and have wide tissue and species applicability. These will be functionalised to culture surfaces to facilitate the isolation of a more homogenous MSC seeding population. This is a key enabler for a more defined therapeutic product.
In addition to isolating a more homogenous starting cell population, there are additional factors which can significantly impact the bioprocessing and manufacture of stem cell therapies, namely the reagents and medium employed [9] . The over-reliance of the cell therapy industry on foetal bovine serum (FBS) for large-scale production of clinical grade MSCs is an impediment to the development of cell-based regenerative medicine. The 2014 Alliance for
Regenerative Medicine (ARM) survey of pharmaceutical and large-cap biotechnology companies identified "product consistency and lack of standards" as the "single greatest challenge facing the field" [10] . In pursuit of a consistent manufacturing process, there is a need to identify and minimise any source of variation. As such, there has been a concerted effort across the cell therapy and wider biopharmaceutical sector to move towards serum and xeno-free medium. Whilst the greatest driver is often safety-oriented with a focus on regulatory compliance, there are also significant concerns about batch-to-batch variability associated with serum (and the impact this has on the process) and supply and availability of GMP-grade foetal bovine serum [1, 11, 12] . It is envisaged that AUTOSTEM's use of a novel, fully-defined growth medium [13] , which does not depend on FBS supplies, to culture a defined MSC population will enable improved process and product consistency and facilitate the development of standard production systems.
Obtaining a sufficient number of hMSCs for a therapy, be it autologous or allogeneic, necessitates ex vivo cell culture. Although multiple cell production systems are available [11] , two of the major cell culture platforms will be considered, a rotating bed bioreactor and microcarrier systems used in conjunction with stirred-tank bioreactors. Microcarriers provide a significantly larger surface area per unit volume compared to other expansion platforms and such systems are scalable, amenable for automation, allow for multiple modes of operation (batch, fed-batch, perfusion) and have a significant heritage in biopharmaceutical production [1] . Members of this consortium demonstrated the first litre-scale expansion of hMSCs on microcarriers in a stirred-tank bioreactor (2.5 L working volume) and developed a scalable harvesting technique to obtain single hMSCs without any adverse effect on cell quality [14] .
The cell density achieved was ~ 1.7 x 10 5 cells/mL, although recent studies by the group and others have demonstrated cell densities approaching clinically-relevant numbers of ~ 1 x 10 6 cells/mL [15, 16] . It is likely with further bioprocess development and parameter optimisation, cell densities will continue to increase, as has been the case with traditional biopharmaceutical development. This, however, potentially brings additional challenges which may not currently be problematic such as mass transfer limitations and large aggregate formation and is something that requires further investigation should this arise.
Accurate monitoring of process parameters remains a challenge and the available sensing technologies tend to be outdated. With the increasing trend in the use of disposable bioreactors there is an associated interest in disposable sensors that can be employed within the equipment.
Current sensors for process monitoring (e.g. PAT sensors in pharmaceutical manufacturing)
are effective for dO2, pH and temperature (chemical and physical parameters) but less effective for key biological parameters such as glucose and lactic acid. They also suffer from coagulation and fouling of sensor heads due to the biological nature of the medium and the product [17] . A miniaturised sensing device is currently under development that can be housed within the bioreactor and continuously monitor the environment. The sensing device takes the form of a free floating probe with a sensing chip and control electronics to control and acquire the data that is encased in robust, biocompatible packaging [18] . Cutting edge semiconductor fabrication technologies are being applied to develop a multi-parametric sensing chip with the potential to monitor key physical, chemical and biological parameters simultaneously in the bioreactor environment [19] . These technologies lend themselves to high volume sensor chip production which will result in cheap and highly reproducible devices. An electrochemical based approach will be applied which allows for micron and nano-scale electrode dimensions to be implemented to meet the sensitivity requirements [20] . with the subject matter or materials discussed in the manuscript apart from that disclosed.
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